MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 573374 | Name: SQ-28429
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SQ-28429, also known as (E)-Aztreonam, is an E-isomer of aztreonam, which is an antiobiotics.Aztreonam is a monocyclic beta-lactam antibiotic (a monobactam) originally isolated from Chromobacterium violaceum. Aztreonam exhibits potent and specific activity in vitro against a wide spectrum of gram-negative aerobic pathogens including Pseudomonas aeruginos. Aztreonam-avibactam is a new combination with activity against multidrug-resistant Klebsiella pneumoniae complex.

Chemical Structure

SQ-28429
SQ-28429
CAS#99341-02-3 (S-isomer)

Theoretical Analysis

MedKoo Cat#: 573374

Name: SQ-28429

CAS#: 99341-02-3 (S-isomer)

Chemical Formula: C13H17N5O8S2

Exact Mass: 435.0519

Molecular Weight: 435.43

Elemental Analysis: C, 35.86; H, 3.94; N, 16.08; O, 29.39; S, 14.73

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
78110-38-0 (Z-isomer) 99341-02-3 (S-isomer)
Synonym
Aztreonam E-isomer,; SQ 28429; SQ-28429; SQ28429; (E)-Aztreonam;
IUPAC/Chemical Name
Propanoic acid, 2-(((1-(2-amino-4-thiazolyl)-2-((2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino)-2-oxoethylidene)amino)oxy)-2-methyl-, (2S-(2alpha,3beta(E)))-
InChi Key
WZPBZJONDBGPKJ-IYZXUIDESA-N
InChi Code
1S/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8+/t5-,7-/m0/s1
SMILES Code
C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N/OC(C)(C)C(=O)O)/c2csc(n2)N
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Klebsiella pneumoniae complex (KPc) is a group of opportunistic pathogens that pose a serious threat to public health. Multidrug resistance is increasing, and limiting therapeutic options. Aztreonam-avibactam (AZA) is a combination of an established β-lactam with a new β-lactamase inhibitor.

Preparing Stock Solutions

The following data is based on the product molecular weight 435.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Sękowska A. Aztreonam-avibactam: a new combination with activity against multidrug-resistant Klebsiella pneumoniae complex. J Antibiot (Tokyo). 2025 Jan 7. doi: 10.1038/s41429-024-00803-6. Epub ahead of print. PMID: 39774263. 2: Posteraro B, De Maio F, Spanu T, Vidal Pereira MA, Fasano FR, Sanguinetti M. Characterization of Metallo β-Lactamase Producing Enterobacterales Isolates with Susceptibility to the Aztreonam/Avibactam Combination. Antibiotics (Basel). 2024 Dec 17;13(12):1221. doi: 10.3390/antibiotics13121221. PMID: 39766611. 3: Lee S, Lee T, Kim MK, Ahn JH, Jeong S, Park KH, Chong Y. 7-O-Carboxylic Acid-Substituted 3-O-Alkyl Difluoroquercetin; An Aztreonam-Potentiating Agent Against Carbapenemase-Producing Pseudomonas aeruginosa Through Simultaneous Inhibition of Metallo-β-Lactamase and Efflux Pump. Antibiotics (Basel). 2024 Dec 10;13(12):1202. doi: 10.3390/antibiotics13121202. PMID: 39766592. 4: Jean SS, Chang HT, Huang CL, Liu IM, Hsieh PC, Hsueh PR. Distributions of plasmidic genes encoding extended-spectrum and AmpC β-lactamases, and susceptibilities of global non-carbapenemase-producing meropenem-resistant Enterobacterales to ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam- avibactam, 2017-2022. J Infect. 2024 Dec 30;90(2):106380. doi: 10.1016/j.jinf.2024.106380. Epub ahead of print. PMID: 39742976. 5: Xiang X, Kong J, Zhang J, Zhang X, Qian C, Zhou T, Sun Y. Multiple mechanisms mediate aztreonam-avibactam resistance in Klebsiella pneumoniae: driven by KPC-2 and OmpK36 mutations. Int J Antimicrob Agents. 2024 Dec 27:107425. doi: 10.1016/j.ijantimicag.2024.107425. Epub ahead of print. PMID: 39734051. 6: Hölsken O, Sponheuer K, Weber F, Martens-Lobenhoffer J, Bode-Böger SM, Kloft C, Treskatsch S, Angermair S. First Clinical Application of Aztreonam-Avibactam in Treating Carbapenem-Resistant Enterobacterales: Insights from Therapeutic Drug Monitoring and Pharmacokinetic Simulations. J Pers Med. 2024 Nov 30;14(12):1135. doi: 10.3390/jpm14121135. PMID: 39728048; PMCID: PMC11676034. 7: Le Terrier C, Nordmann P, Poirel L. 'Potent in-vitro activity of sulbactam- durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates' - Author's reply. Clin Microbiol Infect. 2024 Dec 21:S1198-743X(24)00598-6. doi: 10.1016/j.cmi.2024.12.012. Epub ahead of print. PMID: 39716555. 8: Amoura A, Benchetrit L, Magréault S, Chosidow S, Le Menestrel A, Jullien V, de Lastours V, Chau F, Dion S, Massias L, Fantin B, Lefort A. Impact of the inoculum size on the in vivo activity of the aztreonam-avibactam combination in a murine model of peritonitis due to Escherichia coli expressing CTX-M-15 and NDM-1. Antimicrob Agents Chemother. 2024 Dec 19:e0128822. doi: 10.1128/aac.01288-22. Epub ahead of print. PMID: 39699211. 9: Uzunöner Y, Kansak N, Aksaray S. Investigation of the synergistic effect of ceftazidime-avibactam and aztreonam combination on carbapenem-resistant Klebsiella pneumoniae isolates with 3 different methods. Acta Microbiol Immunol Hung. 2024 Dec 17;71(4):308-314. doi: 10.1556/030.2024.02395. PMID: 39688612. 10: Veeraraghavan B, Walia K, Egli A. Re: 'Potent in-vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates' by Poirel et al. Clin Microbiol Infect. 2024 Dec 11:S1198-743X(24)00596-2. doi: 10.1016/j.cmi.2024.12.010. Epub ahead of print. PMID: 39672465. 11: Al Musawa M, Bleick CR, Herbin SR, Caniff KE, Van Helden SR, Rybak MJ. Aztreonam-avibactam: The dynamic duo against multidrug-resistant gram-negative pathogens. Pharmacotherapy. 2024 Dec;44(12):927-938. doi: 10.1002/phar.4629. Epub 2024 Nov 27. PMID: 39601336; PMCID: PMC11687205. 12: Herrera-Espejo S, Bouvier M, Cordero E, Poirel L, Pachón-Ibáñez ME, Nordmann P. A Selective Culture Medium for Screening Aztreonam-Avibactam Resistance in Enterobacterales and Pseudomonas aeruginosa. Microb Drug Resist. 2024 Dec;30(12):513-520. doi: 10.1089/mdr.2024.0150. Epub 2024 Nov 22. PMID: 39574337. 13: Cai LL, Zhou H, Wu NM, Hong LM, Lin ZH. Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA Adverse Event Reporting System. Expert Opin Drug Saf. 2024 Nov 25:1-20. doi: 10.1080/14740338.2024.2430307. Epub ahead of print. PMID: 39565415. 14: Klein N, Jantsch J, Simon M, Rödel J, Becker SL, Serr A, Steinmann J, Ehrentraut SF, Mollitor E, Hischebeth GTR. In vitro activity of ceftazidime- avibactam/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains. Infection. 2024 Nov 18. doi: 10.1007/s15010-024-02425-4. Epub ahead of print. PMID: 39556165. 15: Sangiorgio G, Calvo M, Stefani S. Aztreonam and avibactam combination therapy for metallo-β-lactamase-producing gram-negative bacteria: a comprehensive review. Clin Microbiol Infect. 2024 Nov 9:S1198-743X(24)00532-9. doi: 10.1016/j.cmi.2024.11.006. Epub ahead of print. PMID: 39528085. 16: Koos G, Rizzo S, Siarakas S, Merlino J. Aztreonam and ceftazidime-avibactam overlay in extensively drug-resistant blaNDM-5, blaKPC-2 and blaOXA-181 carbapenemase-producing ​Klebsiella pneumoniae. Pathology. 2024 Sep 17:S0031-3025(24)00235-6. doi: 10.1016/j.pathol.2024.07.003. Epub ahead of print. PMID: 39505659. 17: Sader HS, Kimbrough JH, Mendes RE, Castanheira M. Antimicrobial susceptibility of enterobacterales causing bloodstream infection in United States medical centres: comparison of aztreonam-avibactam with beta-lactams active against carbapenem-resistant enterobacterales. BMC Infect Dis. 2024 Nov 5;24(1):1242. doi: 10.1186/s12879-024-10133-5. PMID: 39501203; PMCID: PMC11536805. 18: Duehlmeyer S, Meier E, Oermann C. Successful treatment of Stenotrophomonas maltophilia with ceftazidime-avibactam and aztreonam in an individual with cystic fibrosis: A case report. Pediatr Pulmonol. 2024 Oct 25. doi: 10.1002/ppul.27363. Epub ahead of print. PMID: 39451040. 19: Le Terrier C, Nordmann P, Delaval A, Poirel L; NARA Network. Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates. Clin Microbiol Infect. 2025 Jan;31(1):122-124. doi: 10.1016/j.cmi.2024.10.012. Epub 2024 Oct 22. PMID: 39447746. 20: Carmeli Y, Cisneros JM, Paul M, Daikos GL, Wang M, Torre-Cisneros J, Singer G, Titov I, Gumenchuk I, Zhao Y, Jiménez-Rodríguez RM, Liang L, Chen G, Pyptiuk O, Aksoy F, Rogers H, Wible M, Arhin FF, Luckey A, Leaney JL, Pypstra R, Chow JW; COMBACTE-CARE consortium REVISIT study group. Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial. Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00499-7. doi: 10.1016/S1473-3099(24)00499-7. Epub ahead of print. PMID: 39389071.